Novartis

(IN BRIEF) Roche’s Vabysmo® (faricimab) prefilled syringe has received European Medicines Agency approval for treating three major retinal conditions: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion (RVO). Serving over nine … Read the full press release →

(IN BRIEF) TeamViewer has announced the acquisition of 1E, a leader in Digital Employee Experience (DEX) management tools, for $720 million. This strategic move enhances TeamViewer’s position in the digital workplace market by integrating its remote connectivity solutions with 1E’s … Read the full press release →

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). Scemblix achieved significantly higher major … Read the full press release →

(IN BRIEF) Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an adjuvant treatment for high-risk hormone receptor-positive (HR+), HER2-negative early breast cancer (EBC). The approval, based on the Phase III NATALEE trial, … Read the full press release →

(IN BRIEF) Wolters Kluwer has nominated Anjana Harve, currently the EVP and CIO at BJ’s Wholesale Club, for a position on its Supervisory Board, pending approval at an Extraordinary General Meeting (EGM) on October 28, 2024. Harve, a seasoned IT … Read the full press release →

(IN BRIEF) MorphoSys AG has completed its voluntary delisting from the Frankfurt Stock Exchange and Nasdaq Global Market following its acquisition by Novartis. The delisting agreement, announced on June 20, 2024, and the subsequent delisting purchase offer by Novartis were … Read the full press release →

(IN BRIEF) Novartis has presented new data at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress, showcasing the sustained efficacy and safety of remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU). Results … Read the full press release →

(IN BRIEF) Novartis revealed promising data from the ALITHIOS open-label extension study, highlighting the enduring effectiveness of Kesimpta® (ofatumumab) in treating relapsing multiple sclerosis (RMS) over a span of up to six years. The study, presented at the American Academy … Read the full press release →

(IN BRIEF) Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorization for Fabhalta® (iptacopan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who … Read the full press release →

(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release →

(IN BRIEF) Novartis has presented compelling data from the SMART study, reinforcing the clinical advantages of Zolgensma® (onasemnogene abeparvovec) in treating spinal muscular atrophy (SMA) patients weighing ≥ 8.5 kg to ≤ 21 kg, with a mean age of 4.69 … Read the full press release →

(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial … Read the full press release →